目的：探究血清胃蛋白酶原Ⅰ（Pepsinogen Ⅰ,PGⅠ）、PGⅡ以及PGⅠ/PGⅡ比值、胃泌素17（Gastrin-17,G-17）和幽门螺杆菌（Helicobactor pylori,Hp）-IgG抗体检测在临床胃部疾病初筛中的价值。方法：选取2018年7月至2020年7月因胃部疾病于我院消化科住院行胃镜检查者300人为研究对象,根据胃镜及病理检查结果分为慢性浅表性胃炎组、慢性萎缩性胃炎组、胃癌组、胃溃疡组,并抽取同期体检中心健康体检者100人作为对照组,比较各组间的血清PGⅠ、PGⅡ、PGⅠ/PGⅡ比值、G-17水平及Hp-IgG抗体阳性率情况。结果：血清PGⅠ/PGⅡ比值在胃癌组（10.42±4.63）及慢性萎缩性胃炎组（10.54±4.36）中均低于对照组（12.07±6.80）,血清G-17水平在胃癌组[（13.85±27.68） pmmol/L]及慢性萎缩性胃炎组[（9.63±10.82） pmmol/L]中均高于对照组[（6.02±7.30） pmmol/L],血清PGⅠ水平在胃癌组[（123.53±35.45） μg/L]中低于对照组[（148.24±83.85） μg/L]及慢性浅表胃炎组[（141.95±81.11） μg/L],差异均有统计学意义（P均<0.05）。Hp-IgG抗体阳性率在胃癌组（50.75%）及慢性萎缩性胃炎组（50.00%）中均高于对照组（35.00%）,差异有统计学意义（P均<0.05）。结论：血清PGⅠ、PGⅡ、PGⅠ/PGⅡ、G-17及Hp-IgG抗体检测可用于胃部疾病的初筛,以便发现胃癌高危人群,为进一步筛查胃癌提供可靠参考。

Objective: To explore the clinical value of serum PGI, PGII, PGI/PGII, G-17 levels and Hp-IgG antibody in the preliminary screening of gastric diseases. Methods: A total of 300 patients who underwent gastroscopy in the Gastroenterology Department of our hospital from July 2018 to July 2020 due to gastric diseases were selected as the research objects. According to gastroscopy and pathological examinations, they were divided into chronic superficial gastritis group,chronic atrophic gastritis group and gastric cancer group. 100 healthy patients from the physical examination center during the same period were selected as the control group. The serum PGI, PGII, PGI/PGII G17 levels and the positive rate of Hp-IgG antibody in each group were compared. Results: Serum PGI/PGII levels in gastric cancer group(10.42±4.63) and atrophic gastritis group (10.54±4.36) were lower than those in control group (12.07±6.80). Serum G-17 levels in gastric cancer group [(13.85±27.68） pmmol/L] and chronic atrophic gastritis group [(9.63±10.82) pmmol/L] were higher than those in control group [(6.02±7.30) pmmol/L]. The serum PGI level in gastric cancer group[(123.53±35.45) μg/L] was lower than that in the control group[(148.24±83.85) μg/L and chronic superficial gastritis group [(141.95±81.11) μg/L]. The differences were statistically significant (P<0.05). The positive rate of Hp-IgG antibody in gastric cancer group (50.75%) and atrophic gastritis group (50.00%) was higher than that of the control group (35.00%), and the difference was statistically significant (P<0.05). Conclusions: Serum PGI, PGII, PGI/PGII, G-17 levels and Hp-IgG antibody detection can be used for the primary screening of gastric diseases, which can identify high-risk groups of gastric cancer and provide a reliable reference for further screening of gastric cancer.